AXA vs Roche: Founders, CEOs and History
AXA was founded in 1817 by Jacques-Théodore le Carpentier, Claude Bébéar and is led by Thomas Buberl. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.
Company facts
Founders
AXA
Jacques-Théodore le Carpentier
Little is recorded about le Carpentier beyond the founding act itself. In 1817 he and 17 other property owners in Rouen created the Compagnie d'Assurances Mutuelles contre l'Incendie for the departments of the Seine and the Eure, covering their own buildings a…
Claude Bébéar
Claude Bébéar built modern AXA. After joining in 1958 he spent 17 years inside the business, including 1964 to 1966 in Canada creating the life insurance arm of the group subsidiary Provinces Unies, before becoming chief executive in 1975 following Sahut d'Iza…
Roche
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.
CEOs and their tenures
AXA
- Claude Bébéar1975–2000
Chairman and CEO
Bébéar turned a Normandy mutual into a global insurer between 1975 and 2000. He took control of the Drouot Group in 1982, bought Présence in 1986, merged with Compagnie du Midi in 1988, took control of The Equitable in the United States in 1991, National Mutua…
Source - Henri de Castries2000–2016
Chairman and CEO
De Castries ran AXA from May 2000 to September 2016, through the dot-com collapse, the 2008 financial crisis and the euro-area debt crisis, without state support.
Source - Thomas Buberl2016–present
Chief Executive Officer
Buberl became chief executive in September 2016 and refocused AXA on insurance underwriting.
Source
Roche
- Severin Schwan2008–2023
Chief Executive Officer
Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.
Source - Thomas Schinecker2023–present
Chief Executive Officer
Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.
Source
Timeline: AXA and Roche side by side
1817AXA
Founding of the Compagnie d'Assurances Mutuelles contre l'Incendie
Jacques-Théodore le Carpentier and 17 other property owners in Rouen set up a mutual fire insurance company, the earliest predecessor of AXA. It stayed a Normandy mutual, later called Ancienne Mutuelle, for more than a century.
1896Roche
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
1898Roche
Commercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
1934Roche
First Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
1963Roche
Launch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
1968Roche
Establishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
1975AXA
Claude Bébéar becomes chief executive
Bébéar, recruited in 1958 by André Sahut d'Izarn, took over the Anciennes Mutuelles group in 1975 after Sahut d'Izarn's death and the settlement of a strike that had paralysed the company in April 1974.
1982AXA
Takeover of the Drouot Group
Bébéar took control of the Drouot Group, then the leading private French insurance group, and became its chairman alongside his role at Mutuelles Unies.
1985AXA
Creation of the AXA name
The group adopted the invented name AXA, short and pronounceable in any language, and Bébéar moved from running the insurance companies to chairing the group.
1986AXA
Acquisition of the Présence Group
AXA bought the Présence Group in April 1986, continuing the consolidation of French insurers.
1988AXA
Merger with Compagnie du Midi
The merger with Compagnie du Midi made AXA the second-largest French insurance group behind UAP and brought Equity and Law, then the sixth-largest life insurer in the United Kingdom. Bébéar was elected Manager of the Year the same year.
1991AXA
Control of The Equitable in the United States
After a failed attempt to buy Farmers, AXA agreed in July 1991 to demutualise and take control of The Equitable, then the fifth-largest life insurer in the United States, which also brought Alliance Capital Management.
1996AXA
Acquisition of UAP
AXA bought UAP, a French insurer twice its size, doubling its French business and reaching critical mass in the United Kingdom, Belgium and Germany. The merger took effect in 1997.
1999AXA
Guardian Royal Exchange and Nippon Dantai
Guardian Royal Exchange joined AXA in early 1999, adding scale in United Kingdom property, casualty and health insurance, and AXA took control of Nippon Dantai, then the thirteenth-largest life insurer in Japan.
2006AXA
Acquisition of Winterthur
AXA agreed to buy Winterthur from Credit Suisse for ~$14.8 billion (CHF 12.3 billion), about $8.93 billion (EUR 7.9 billion) in cash, strengthening its position in Switzerland, Germany and central and eastern Europe.
2008Roche
Severin Schwan becomes CEO
Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
2009Roche
Full Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
2011AXA
Sale of AXA Canada
AXA sold its Canadian operations to Intact Financial Corp. for ~$1.87 billion (C$2.6 billion) as part of a portfolio review.
2018AXA
Acquisition of XL Group
AXA bought XL Group for $15.3 billion in cash, shifting the group toward commercial property and casualty lines and creating the AXA XL platform.
2018Roche
Foundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
2023Roche
Acquired Telavant
F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
2024AXA
Launch of the Unlock the Future plan
With its 2023 results in February 2024 AXA presented a 2024 to 2026 plan targeting underlying earnings per share growth of 6% to 8% a year, an underlying return on equity of 14% to 16% and a new capital management policy.
2025AXA
Sale of AXA Investment Managers to BNP Paribas
AXA completed the sale of AXA Investment Managers to BNP Paribas Cardif on July 1, 2025 for ~$5.76 billion (EUR 5.1 billion) in cash, a total transaction value of ~$6.1 billion (EUR 5.4 billion), and signed a long-term agreement for BNP Paribas to manage a lar…
2025AXA
Death of founder Claude Bébéar
AXA announced on November 4, 2025 that Claude Bébéar, its founder and Honorary Chairman, had died at the age of 90. He ran the group from 1975 to 2000 and created the AXA name in 1985.
2025Roche
Group Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
Acquisitions
AXA
- Prima Assicurazioni (51% stake)2025Undisclosed
- Laya Healthcare2023Undisclosed
- XL Group2018$15.3B
- Winterthur2006$10B
- UAP (Union des Assurances de Paris)1996$7.8B
- The Equitable (US)1991$1B
Roche
- PathAI2026$1.1B
- 89bio2025$3.5B
- Telavant2023$7.1B
- Carmot Therapeutics2023$2.7B
- Foundation Medicine2018$2.4B
- ForSight VISION42017Undisclosed
Questions about AXA vs Roche
Who is the CEO of AXA SA and F. Hoffmann-La Roche AG?
AXA SA is led by Thomas Buberl and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AXA SA founded vs F. Hoffmann-La Roche AG?
AXA SA was founded in 1817 — 79 years before F. Hoffmann-La Roche AG, which was founded in 1896. AXA SA's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger F. Hoffmann-La Roche AG.
How many employees does AXA SA have compared to F. Hoffmann-La Roche AG?
AXA SA employs approximately 156,000 people, while F. Hoffmann-La Roche AG employs approximately 112,774. AXA SA has the larger workforce at 156,000 employees, compared to F. Hoffmann-La Roche AG's 112,774. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AXA SA and F. Hoffmann-La Roche AG headquartered?
AXA SA is headquartered in France and F. Hoffmann-La Roche AG is headquartered in Switzerland. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AXA SA and F. Hoffmann-La Roche AG?
AXA SA was founded by Jacques-Théodore le Carpentier, Claude Bébéar. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.
Which company has a longer operating history — AXA SA or F. Hoffmann-La Roche AG?
AXA SA has been operating for approximately 209 years, making it the more established of the two companies. F. Hoffmann-La Roche AG has been in operation for around 130 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AXA vs Roche overview